- Home
- GLRE vs ORGO Comparison
GLRE vs ORGO Comparison
Compare GLRE & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | ORGO |
|---|---|---|
| Founded | 2004 | 1985 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 514.0M |
| IPO Year | 2007 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GLRE | ORGO |
|---|---|---|
| Price | $14.14 | $2.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 80.6K | ★ 661.5K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | ★ 0.74 | 0.15 |
| Revenue | ★ $696,026,000.00 | $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.84 |
| P/E Ratio | ★ $19.27 | $19.37 |
| Revenue Growth | 4.34 | ★ 17.04 |
| 52 Week Low | $11.57 | $2.61 |
| 52 Week High | $15.06 | $7.08 |
Technical Indicators
Market Signals| Indicator | GLRE | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 24.47 |
| Support Level | $12.49 | $2.61 |
| Resistance Level | $14.60 | $3.28 |
| Average True Range (ATR) | 0.29 | 0.23 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 47.52 | 2.00 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.